论文部分内容阅读
上海三维制药公司研制的氟康唑原料及胶囊剂于1995年8月1日由上海市医药局组织通过鉴定。 氟康唑由美国辉瑞公司于1980年研制成功,1988年上市,商品名“大扶康”(Difucan),1990年FDA批准在美国上市后,至今已在30多个国家上市,1994年销售额近10亿美元,列入“重磅炸弹型”药品。 氟康唑的特点是高效、低毒、口服吸收好、生物利用度高,为深部真菌感染的首选药物。本品服用后1～2小时内达血峰浓度,生物利用度可达静注的90％以上,自由分布
Shanghai three-dimensional pharmaceutical company developed fluconazole raw materials and capsules on August 1, 1995 by the Shanghai Municipal Bureau of Pharmacy identified. Fluconazole was successfully developed by Pfizer in 1980 and was launched in 1988 under the brand name Difucan. Since its listing in the United States in 1990, fluconazole has been listed in more than 30 countries so far. Its sales in 1994 Nearly 1 billion US dollars, included in the “blockbuster” drugs. Fluconazole is characterized by high efficiency, low toxicity, good oral absorption, high bioavailability, the preferred drug for deep fungal infections. This product is taken within 1 to 2 hours after peak blood concentration, bioavailability of up to 90% of the static injection, free distribution